Main uses of Resolor

Resolor is a medication indicated for the symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief. Chronic constipation is a condition characterized by infrequent bowel movements or difficult passage of stools over an extended period.

Unlike stimulant laxatives that irritate the lining of the bowel, Resolor belongs to a class of medicines known as selective serotonin receptor agonists. It targets specific 5-HT4 receptors in the gut to stimulate intestinal motility.

Therapeutic benefits

The primary objective of treatment with Resolor is to improve bowel function and alleviate the discomfort associated with chronic constipation. When the medication is effective, patients may experience several clinical benefits:

• Increased frequency of bowel movements: The medication helps to restore a more regular rhythm to the digestive system.
• Improved stool consistency: By enhancing the transit time through the colon, it can help prevent stools from becoming excessively hard or dry.
• Reduction in straining: Improved motility often leads to a more spontaneous and less difficult evacuation process.
• Relief of abdominal symptoms: Successful treatment can reduce common associated symptoms such as bloating, abdominal pain, and the sensation of incomplete evacuation.

Mechanism of action

The active substance in Resolor, prucalopride, works by mimicking the action of serotonin, a naturally occurring chemical in the body that plays a key role in the movement of the digestive tract. By binding to the 5-HT4 receptors, it triggers the muscular contractions required to move waste through the colon. This targeted approach is designed to restore the natural propulsive activity of the intestines rather than simply softening the stool or causing a temporary irritant effect.

The official regulatory documents strictly define the populations eligible and ineligible for Resolor (Prucalopride) based on age, physiological status, and underlying comorbidities.

Eligibility Classification	Status According to Regulatory Labels
Approved Age Group	Adults (18 years and older).
Contraindicated Conditions	Absolute non-eligibility is defined by severe gastrointestinal disorders, including intestinal perforation or obstruction, obstructive ileus, and severe inflammatory conditions like Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum. Use is also prohibited in patients with known hypersensitivity or those with renal impairment requiring dialysis.
Restricted Populations	Children and adolescents younger than 18 years are not recommended to use the medicine as safety and efficacy have not been established. Use is also not recommended during pregnancy or breastfeeding. Women of childbearing potential must use effective contraception during treatment.
Organ Function Restrictions	Individuals with severe renal impairment (creatinine clearance <30 mL/min) require special regulatory consideration, and severe hepatic impairment (Child-Pugh Class C) mandates that caution be exercised due to limited data.

These constraints ensure that use of the medicine is confined to the specific adult population studied and that individuals with severe underlying medical conditions or physiological states that could be negatively impacted are officially excluded.

Interactions with other medicines and products

The interaction profile for Prucalopride (Resolor) is officially classified as having a low pharmacokinetic interaction potential. Regulatory studies confirm the drug does not inhibit specific CYP450 enzymes at clinically relevant concentrations.

Documented Pharmacokinetic and Transporter Interactions

Interaction Type	Interacting Substance	Official Regulatory Statement
Exposure Increase (Prucalopride)	Potent P-glycoprotein (P-gp) Inhibitors (e.g., Ketoconazole, Verapamil, Cyclosporine A)	Co-administration with Ketoconazole increases Prucalopride's systemic exposure (AUC) by approximately 40%. This increase is generally not considered clinically relevant by regulators, but similar effects are expected with other potent P-gp inhibitors. Prucalopride is a weak P-gp substrate.
Effect on Co-Medication	Erythromycin	Co-administration resulted in a 30% increase in the plasma concentrations of Erythromycin.
Reduced Efficacy	Fosfomycin	Prucalopride can increase gastrointestinal transit, potentially reducing Fosfomycin absorption. The official guidance suggests administering the dose at a different time of day.
No Relevant Effect	Alcohol, Warfarin, Digoxin, Paroxetine	Prucalopride had no clinically relevant effects on the pharmacokinetics of these agents.

Population-Specific Interaction Notes

Patients with severe renal impairment (creatinine clearance < 30 mL/min) exhibit a substantial increase in Prucalopride systemic exposure due to the drug's primary route of excretion. Exposure is also documented to be higher in older people, which is attributed to diminished renal function. The regulatory label also notes that severe diarrhea, if it occurs, may reduce the efficacy of oral contraceptives.

Resolor (Prucalopride) is categorized as a prokinetic agent whose mechanism involves engaging the neural pathways that govern muscle movement in the colon. Its action is centered on selective receptor activation and the subsequent cascade that strengthens propulsive motility.

Targeted Activation of the Serotonin 5-HT₄ Receptor

The drug acts as a selective agonist of the Serotonin 5-HT₄ receptor, which is expressed on the neurons of the Enteric Nervous System (ENS) in the gut wall. This targeted interaction initiates a molecular signal that amplifies the natural motor commands of the large intestine, which results in action primarily focused on colonic function.

Neurotransmission and Propulsive Motility

Activating the 5-HT₄ receptors leads to the enhanced release of the excitatory neurotransmitter Acetylcholine (ACh) from motor nerve endings. The resulting surge in cholinergic signaling directly stimulates the colon's smooth muscle layers, generating and strengthening the coordinated contractions known as Giant Migrating Contractions (GMCs). The resulting physiological effect of this mechanism is the acceleration of colonic transit time.

Administration Guidelines

Resolor (prucalopride) is an oral medication. The following details outline the methods for dosing, frequency, and use in specific populations.

Route and Timing:

• Route of Administration: Oral (tablet).
• Frequency: Once daily.
• Timing: The tablet can be taken at any time of the day, with or without food.

Dosing Rules:

The recommended dose for adults is 2 mg once daily. Certain patient populations require a modified starting dose:

Patient Group	Recommended Daily Dose	Constraint/Condition
Adults (<65 years)	2 mg	Maximum daily dose
Elderly (≥65 years)	Start with 1 mg, increase to 2 mg if needed	Initial dose may be increased if well-tolerated and required for efficacy
Severe Renal Impairment (GFR < 30 mL/min/1.73 m^2)	1 mg	Reduced dose is mandatory
Severe Hepatic Impairment (Child-Pugh Class C)	Start with 1 mg, may increase to 2 mg	Use with caution, dose adjustment needed

Missed Dose and Treatment Duration:

If a dose is missed, the next scheduled dose should be taken at the usual time; a double dose should not be taken to compensate. The efficacy of the treatment should be re-evaluated if no benefit is observed after 4 weeks of once-daily intake. Efficacy beyond 12 weeks has not been established, and the benefit of continued treatment must be reassessed at regular intervals.

Research Evidence / Overview of Studies for Resolor

Evidence for Use in Chronic Constipation (CC) and CIC

The core research base for Resolor includes multiple short-term, placebo-controlled clinical trials (RCTs), followed by open-label extension studies lasting up to two years. These studies were designed to assess how the medicine was observed to compare to an inactive substance (a placebo) in adult patients experiencing chronic constipation, particularly those who had found standard laxatives insufficient for relief.

Researchers used these trials to explore how symptoms change over time by measuring how frequently participants achieved a certain number of spontaneous complete bowel movements (SCBMs) per week. Findings describe patterns observed in the studies where, after the defined short period (typically 12 weeks), the proportion of patients receiving the medicine who reported reaching the target frequency of SCBMs was higher than the proportion reported by those receiving placebo. Research highlights changes measured during the study period concerning patient-reported outcomes describing perceived discomfort and changes in scores on quality of life questionnaires.

Long-Term Studies and Follow-Up Data

While the main evidence for initial effects comes from short-term RCTs, the research landscape also includes open-label extension studies. These studies followed patients for longer durations, some for up to two years, to continue observing how symptoms evolved in the observed populations. These studies describe patterns observed in the studies related to the reported SBM frequency over the extended time frame. The evidence contributes to understanding symptom patterns over time but the lack of a placebo group in these extension phases means that long-term effects are not fully established through comparative research.

Evidence in Special Populations

Resolor was evaluated in certain subgroups through sub-analyses of the main trials, particularly concerning older adults (those aged 65 and above). Research described patterns related to these specific populations, and findings indicate that the patterns of change measured were broadly consistent with those observed in the overall adult patient population studied. However, data for certain groups remain insufficient, especially for the most frail older patients, as they were often not included in the initial trials.

What Research Gaps and Uncertainties Remain

The evidence highlights what is known—and what is still uncertain. A key limitation is that follow-up durations were limited for the controlled comparison studies. Data for certain groups, such as children, pregnant individuals, or those with severe or unstable health conditions, remain insufficient or nonexistent. The long-term impact on functional limitations and quality of life remains an area where more evidence is needed.

Key Studies & References

1. A placebo-controlled trial of prucalopride for severe chronic constipation
2. Prucalopride for the treatment of chronic constipation in women (NICE Technology Appraisal Guidance 211)

Common questions about Resolor (FAQ)

Q: Is Resolor the same as other laxatives, or does it work differently?

Resolor is classified as a prokinetic agent, which means it works by targeting the natural movement function of the colon. According to official product information, it acts as a selective serotonin 5-HT₄ receptor agonist. This mechanism is different from that of traditional laxatives, as it specifically stimulates neural pathways to encourage colonic movement.

Q: What kind of constipation is Resolor used for?

Official documents state that Resolor is indicated for the symptomatic treatment of chronic idiopathic constipation (CIC) in adults. It is typically prescribed for individuals who have previously tried other laxatives and did not achieve adequate relief from their chronic symptoms.

Q: Does Resolor treat the cause of constipation or just the symptoms?

Resolor works to address the functional issue of sluggish colon movement by stimulating what is known as propulsive motility. By strengthening the movement of the large intestine, the medicine helps to accelerate transit time and increase the frequency of bowel movements.

Q: Can Resolor be taken for occasional constipation?

The medicine is officially indicated for the treatment of chronic idiopathic constipation. This classification means it is intended for a persistent, long-term condition. It is not indicated for occasional or acute instances of constipation.

Q: Are there any foods or drinks I need to avoid while using Resolor?

According to official administration guidelines, Resolor can be taken at any time of the day, with or without food. Regulatory documents do not specify any particular foods or non-alcoholic drinks that need to be avoided during treatment.

Q: Does Resolor cause weight changes?

Clinical studies list decreased appetite as a common adverse reaction. Weight gain or loss itself is not specifically listed as a common or very common side effect in official documents.

Q: Can Resolor be used by people with diabetes?

Official product information advises that caution should be exercised when the medicine is used in patients with severe and clinically unstable concomitant diseases, which may include endocrine disorders. The requirement for caution in these patient populations is based on regulatory consideration of specific health statuses.

Q: Is it safe to take Resolor long-term?

Research evidence indicates that efficacy beyond 12 weeks has not been fully established in controlled studies. For this reason, the benefit of continued treatment requires formal reassessment at regular intervals as specified by regulatory guidance.

Q: Does Resolor affect blood pressure or heart rate?

Palpitations, which are changes in heart rhythm perception, have been listed as an uncommon side effect. Official documents also note that there is no clinically important effect on the QT interval, which relates to the heart's electrical activity, at the recommended dose.

Q: What should I do if I experience severe stomach pain while taking Resolor?

Abdominal pain is listed as a very common side effect, especially when first starting the medication. However, the medicine is strictly contraindicated in patients who have a severe intestinal perforation or obstruction. Official documentation describes the need for professional assessment when certain severe symptoms are present.

Q: What is the recommended duration of treatment with Resolor?

According to official regulatory sources, if the medicine is not effective and no benefit is observed after four weeks of once-daily intake, the situation should be formally re-examined. The benefit of continuing treatment must be carefully reconsidered at that point.

Q: Does Resolor interact with antidepressant medications?

Official interaction studies confirmed no clinically relevant effect on the plasma concentrations of the antidepressant Paroxetine. Regulatory documents note the need to be aware of the potential for suicidal ideation and behavior in all patients, regardless of concomitant use with other medications.

Q: Is Resolor a stimulant laxative?

Resolor is classified as a selective serotonin 5-HT₄ receptor agonist, which is defined as a prokinetic agent. This mechanism of action is distinct from that of traditional stimulant laxatives, which may work by a different pathway in the bowel.

Q: Can men and women both use Resolor?

The medicine is indicated for use in adult patients, meaning both men and women. However, official warnings state that the use of effective contraception is a necessary consideration for women of childbearing potential during treatment.

Q: Does Resolor cause fluid loss or dehydration?

Diarrhea is listed as a very common adverse reaction, particularly at the beginning of treatment. This symptom is associated with fluid loss, a factor noted in the product information.

Q: Will taking Resolor affect my ability to drive or operate machinery?

Official product information indicates that the medicine may have a minor influence on the ability to drive and use machines. This is because side effects such as dizziness and fatigue have been observed, especially when first starting treatment.

Q: Are there specific symptoms that Resolor is not designed to treat?

Resolor is specifically designed to treat chronic idiopathic constipation by promoting colon movement. It is strictly contraindicated in patients with severe inflammatory bowel conditions, such as Crohn’s disease or ulcerative colitis.

Q: Is Resolor a new drug or has it been available for a while?

Official documents indicate that the medicine has extensive clinical and market experience. It has been marketed in multiple countries worldwide since its first approval in 2009.

Q: Does Resolor have different recommended uses in different countries?

The core indication approved in the US is largely consistent with its regulatory approval and use in other major global regions. The medicine is consistently designated for the treatment of chronic idiopathic constipation in adults.

Q: Can I take Resolor if I am sensitive to lactose?

The product contains lactose monohydrate as an excipient. Due to this component, the medicine is noted as being unsuitable for patients who have rare hereditary problems of galactose intolerance.

How to Store and Dispose of Resolor (Prucalopride)

Resolor must be stored at a temperature below 30 C (86 F). The medicine is required to be kept in its original packaging to ensure its protection from moisture, as stated in official labeling.

Child Safety Storage

The tablets must be kept out of the sight and reach of children as a mandatory safety requirement.

Disposal Instructions

Unused Resolor and related waste material must be disposed of in accordance with local requirements. It is explicitly stated that the medicine must not be discarded via wastewater or household waste. Patients should consult a pharmacist regarding the proper procedure for disposal of unused or expired product.